Ivonescimab Shows Overall Survival Benefit Over Keytruda in Head-to-Head NSCLC Trial
Akeso and Summit Therapeutics reported that their PD‑1×VEGF bispecific antibody ivonescimab improved overall survival versus Merck’s Keytruda in a direct comparison trial for first‑line PD‑L1‑positive NSCLC, though market reaction was muted.